Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors.
O'Connor, Caitlin M
Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors. [electronic resource] - Oncogene 01 2020 - 703-717 p. digital
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
1476-5594
10.1038/s41388-019-1012-2 doi
Amino Acid Substitution
Arginine--genetics
Calmodulin-Binding Proteins--metabolism
Carcinogenesis--drug effects
Cell Line, Tumor
Drug Resistance, Neoplasm--genetics
Humans
MAP Kinase Signaling System--drug effects
Membrane Proteins--metabolism
Mitogen-Activated Protein Kinase Kinases--antagonists & inhibitors
Molecular Dynamics Simulation
Mutagenesis, Site-Directed
Mutation
Neoplasms--drug therapy
Nerve Tissue Proteins--metabolism
Protein Kinase Inhibitors--pharmacology
Protein Phosphatase 2--genetics
Recombinant Proteins--genetics
Transfection
Tyrosine--genetics
Xenograft Model Antitumor Assays
Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors. [electronic resource] - Oncogene 01 2020 - 703-717 p. digital
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
1476-5594
10.1038/s41388-019-1012-2 doi
Amino Acid Substitution
Arginine--genetics
Calmodulin-Binding Proteins--metabolism
Carcinogenesis--drug effects
Cell Line, Tumor
Drug Resistance, Neoplasm--genetics
Humans
MAP Kinase Signaling System--drug effects
Membrane Proteins--metabolism
Mitogen-Activated Protein Kinase Kinases--antagonists & inhibitors
Molecular Dynamics Simulation
Mutagenesis, Site-Directed
Mutation
Neoplasms--drug therapy
Nerve Tissue Proteins--metabolism
Protein Kinase Inhibitors--pharmacology
Protein Phosphatase 2--genetics
Recombinant Proteins--genetics
Transfection
Tyrosine--genetics
Xenograft Model Antitumor Assays